“Is the Compulsory Licensing Mechanism Guaranteed by TRIPS the Best Remedy to Improve Access to Biological Therapies Worldwide?”, EEJTR, vol. 3, no. 1, pp. 39–52, Jun. 2019, doi: 10.15290/eejtr.2019.03.01.03.